Marieke van Son

187 GENERAL DISCUSSION AND FUTURE PERSPECTIVES 28. Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Ad- vanced Prostate Cancer-Updated Diag- nostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Mem- brane Antigen-avid Lesions: A System- atic Review and Meta-analysis. Eur Urol. 2020;77(4):403-17. 29. Abd-AlazeezM, RamachandranN, Dikaios N, Ahmed HU, Emberton M, Kirkham A, et al. Multiparametric MRI for detec- tion of radiorecurrent prostate cancer: added value of apparent diffusion coef- ficient maps and dynamic contrast-en- hanced images. Prostate cancer and prostatic diseases. 2015;18(2):128-36. 30. Arumainayagam N, Kumaar S, Ahmed HU, Moore CM, Payne H, Freeman A, et al. Accuracy of multiparametric magnet- ic resonance imaging in detecting recur- rent prostate cancer after radiotherapy. BJU international. 2010;106(7):991-7. 31. Yorozu A, Soyano T, Sutani S, Saito S, Toya K, Shiraishi Y. Patterns of Re- currence for Prostate Cancer Patients Treated with Brachytherapy-based Ra- diotherapy. Int J Radiat Oncol Biol Phys. 2019;105(1):E316. 32. Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Kollmeier M, et al. Ana- tomical Patterns of Recurrence Follow- ing Biochemical Relapse in the Dose Escalation Era of External Beam Radio- therapy for Prostate Cancer. The Journal of urology. 2015;194(6):1624-30. 33. Chopra S, Toi A, Haider MA, Milosevic M, Bristow RG, Bayley A, et al. Spatial patterns of local recurrence after radio- therapy for prostate cancer. Radiother Oncol. 2009;92:S22. 34. Jones JS. Radiorecurrent pros- tate cancer: an emerging and large- ly mismanaged epidemic. Eur Urol. 2011;60(3):411-2. 35. Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M. Postra- diotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys. 2000;48(2):355-67. 36. van den Bergh RC, van Casteren NJ, van den Broeck T, Fordyce ER, Gietz- mann WK, Stewart F, et al. Role of Hor- monal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treat- ment: A Systematic Review. Eur Urol. 2016;69(5):802-20. 37. Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, et al. Long-term risk of clinical pro- gression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recur- rence. Eur Urol. 2011;59(6):893-9. 38. Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic Value of Biochemical Recur- rence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol. 2019;75(6):967-87. 39. Peters M, Kanthabalan A, Shah TT, McCartan N, Moore CM, Arya M, et al. Development and internal validation of prediction models for biochemical fail- ure and composite failure after focal sal- vage high intensity focused ultrasound for local radiorecurrent prostate cancer: Presentation of risk scores for indi- vidual patient prognoses. Urol Oncol. 2018;36(1):13 e1- e0. 40. Spiess PE, Katz AE, Chin JL, Bahn D, Cohen JK, Shinohara K, et al. A pretreat- ment nomogram predicting biochemi- cal failure after salvage cryotherapy for locally recurrent prostate cancer. BJU international. 2010;106(2):194-8. 10